GC Biopharma's BARYTHRAX Becomes World's First Recombinant Anthrax Vaccine to Show Protective Immunity in Phase 2 Trial
Key Insights
GC Biopharma (search)'s BARYTHRAX (search), the world's first recombinant anthrax (search) vaccine, demonstrated protective antibody levels exceeding pre-defined thresholds in a Phase 2 trial with 240 participants.
The randomized, double-blind, placebo-controlled study showed the vaccine elicited robust immunogenicity with only mild, temporary adverse events and no serious safety concerns.
BARYTHRAX (search) represents Korea's first domestically developed recombinant anthrax (search) vaccine, offering advantages over traditional live attenuated bacterial vaccines including improved safety and rapid mass production capability.
GC Biopharma (search) announced that its groundbreaking anthrax (search) vaccine BARYTHRAX (search) (GC1109) has achieved a significant milestone, with Phase 2 clinical trial results published in the international journal Vaccine demonstrating both safety and protective immunogenicity. The vaccine represents the world's first recombinant protein-based anthrax vaccine, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (search) (KDCA (search)).
Phase 2 Trial Design and Results
The randomized, double-blind, placebo-controlled Phase 2 clinical trial was approved by the Ministry of Food and Drug Safety (MFDS) and conducted across five major Korean hospitals: Seoul National University Hospital, The Catholic University of Korea St. Vincent's Hospital, Korea University Ansan Hospital, Soon Chun Hyang University Hospital Seoul, and Hallym University Sacred Heart Hospital. A total of 240 healthy adult subjects participated in the study.
The trial's primary objective was to evaluate the safety and immunogenicity of BARYTHRAX (search) compared to placebo. Results demonstrated that the vaccine elicited antibodies that neutralized the anthrax (search) toxin at levels exceeding the pre-defined protective threshold, indicating robust immunogenicity and suggesting clinically meaningful protection against anthrax infection.
Safety Profile Confirms Favorable Tolerability
Safety assessments revealed that adverse events in the BARYTHRAX (search) group were predominantly mild and temporary, including injection site pain, myalgia, fatigue, and malaise. Critically, no cases of acute adverse reactions or deaths were reported during the study period, confirming a favorable safety profile for the vaccine.
Dr. Nam Joong Kim, the principal investigator and professor at Seoul National University Hospital, emphasized the significance of these findings: "This clinical research exemplifies successful academia-industry collaboration and represents a significant milestone in the development of safe and effective vaccines."
Technological Innovation and Manufacturing Advantages
BARYTHRAX (search) is produced using recombinant technology to express and purify solely the Protective Antigen (search) (PA) protein from Bacillus anthracis (search), the key component of the anthrax (search) toxin. This approach offers significant advantages over traditional vaccine development methods that use live attenuated bacteria, providing enhanced safety and enabling rapid mass production when needed.
The vaccine represents Korea's 39th New Drug and 3rd New Drug Vaccine, marking a significant achievement in the country's pharmaceutical development capabilities.
Clinical and Strategic Implications
Dr. Chang Kyung Kang of Seoul National University Hospital, the lead author of the publication, noted: "We are thrilled to have our study result published in a globally renowned academic journal Vaccine, once again recognizing its clinical significance and value."
Jae-Uk Jeong, Head of R&D at GC Biopharma (search), commented on the broader implications: "The clinical trial has successfully demonstrated the efficacy and safety of BARYTHRAX (search). This domestically developed anthrax (search) vaccine is poised to make a significant contribution to strengthening our national pandemic preparedness."
Addressing Biodefense Needs
Anthrax (search) is classified as a potential bioterrorism agent, as aerosolized anthrax spores can cause fatal respiratory infections. The development of BARYTHRAX (search) addresses critical biodefense preparedness needs, particularly given anthrax's classification as a zoonotic disease that can infect both humans and animals.
Dr. Kim highlighted the vaccine's potential impact on infectious disease research: "We anticipate that the successful development of Korea's first recombinant anthrax (search) vaccine will serve as a stepping stone for advancing research on infectious diseases and boosting vaccine localization."
The successful Phase 2 results position BARYTHRAX (search) as a potentially significant advancement in anthrax (search) prevention, combining innovative recombinant technology with demonstrated clinical efficacy and safety.